Merck
HomeWebinarsAssay Development for Quantification of Low-Abundance Proteins Using Single Molecule Counting

Assay Development for Quantification of Low-Abundance Proteins Using Single Molecule Counting



WEBINAR

It is known that Huntington’s Disease (HD) is caused by the expression of a mutated form of the Huntingtin protein containing a polyglutamine (polyQ) repeat, with the length of the repeat correlating to increased severity of the disease. Since concentrations of total and mutant HTT in premanifest and controls groups are extremely low, it is imperative the assays are able to reach fM levels of sensitivity. Employing SMC™ technology we are able to provide the HD community with tools to enable better understanding of the disease and to assist in the development of new therapeutics. During this webinar we will review data from the development and validation of the High Sensitivity SMC™ Immunoassays for the Quantification of mHTT and total HTT.

For Research Use Only. Not For Use In Diagnostic Procedures.

Request Info on SMC™ Assays

Speaker

Sarah Hamren

Sarah Hamren

Merck

Head of Custom Assays & Sample Testing

Sarah Hamren led the SMC® Custom Assay and Sample Testing group since 2015. She has over 30 years of experience in biopharma research and development. Previously the Director of Assay Development of the Life Science Division for Singulex® Inc., Sarah was responsible for the successful transfer of the Singulex® Life Science business unit since its 2015 acquisition. She is co-author on 15 peer-reviewed publications and holds two U.S. patents. Sarah’s 12 years of experience effectively partnering with a broad array of clients have culminated in hundreds of successful biomarker assay development projects. She has proven success overcoming the limitations of challenging sample types and very small sample volumes while at the same time adhering to project deadlines, budgets, and the highest standards of quality control.